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Background & Objectives
▪ Glycaemic control (GC) targeting normoglycaemic ranges in ICU patients has shown improved
outcomes but was proven difficult to achieve safely, increasing risk of hypoglycaemia.
▪ STAR is a model-based GC protocol with proven safety and performance. It uses a unique risk-
based dosing approach accounting for both intra- and inter- patient variability (Figure 1).
▪ This study compares safety and efficacy of intermediate clinical results of the STAR-Liège trial at
the University Hospital of Liège, Belgium, with retrospective data from patients under the
standard protocol (SP).
Fig. 1. Current patient-specific insulin sensitivity (SI) is identified using a mathematical model (1). Future SI is forecast using a stochastic model (2). 
Using distribution of future SI, STAR (3) optimises insulin-nutrition rates to overlap predicted BG outcomes with the safe target band.
Methods
Ethics approval was granted by the University Hospital of Liège Ethics Committee for the STAR-
Liège clinical trial. STAR-Liège offers 1-3 hourly blood glucose (BG) measurement options.
▪ Target band: 80 – 145 mg/dL (100 – 150 mg/dL for SP)
▪ Starting criteria: 2 BG measurements > 145 mg/dL
▪ Stopping criteria: BG stable for 6h at low insulin rates (≤ 2U/h) or 72h after inclusion
▪ Insulin: Max. 9U/h with maximum increment of 2U/h
▪ Nutrition: Decrease to a min. of 30% original goal feed
Results
▪ Clinical results of STAR are compared to retrospective patients (Table 1).
Table 1 – Clinical data from 10 STAR patients and 20 retrospective patients. BG is resampled hourly. Results are given as median [IQR].
Conclusions
▪ It is possible to provide safe, and effective control for all patients despite lower intermediate
glycaemic target ranges, using model-based, risk-based dosing of insulin and nutrition.
▪ These results are encouraging, comparable to previous studies, and support STAR’s risk-
based dosing approach as a robust solution across different ICU settings and usages.
Stochastic TARgeted (STAR) glycaemic control: improved performances and safety for all
STAR SP
# Patients 10 20
Total hours 455 5006
Average measurements per day 12 7
Cohort BG (mg/dL) 118 [109 129] 139 [117, 160]
Per-patient median insulin rate (U/hr) 3.0 [2.0 4.0] 2.5 [2.0, 3.0]
Per-patient median dextrose rate (g/hr) 7.0 [4.7, 8.2] 9.8 [8.6, 11.5]
Per-patient median dextrose rate (%Goal) 90 [60 100] /
% BG in 80-145 mg/dL 89 55
% BG in 100-150 mg/dL 84 54
% BG in 145-180 mg/dL 9 31
% BG > 180 mg/dL 2 13
% BG < 80 mg/dL 0.5 1
% BG < 40 mg/dL 0 0
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